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TO THE EDITOR
The phenomenon of multidrug resis-
tance (MDR) is defined as the ability of
a cell to show resistance to a wide
variety of structurally and functionally
unrelated molecules and is, in large
part, related to membrane efflux trans-
porters because its principal mechan-
ism is the active transport of substrates
out of the cell (Higgins, 2007). Multi-
drug transporters have broad specificity
for a wide range of chemically unre-
lated agents (Higgins, 2007). One
superfamily of active membrane trans-
porters is the family of ATP-binding
cassette (ABC) transport proteins that
use the energy of ATP hydrolysis to
transport large organic molecules either
directly or, in case of many natural
substrates, conjugated to acidic ligands,
such as glutathione, glucuronate, or
sulfate out of the cell (Ko¨nig et al.,
1999). Although most ABC transporters
were discovered as drug transporters,
they frequently transport a wide range
of physiological substrates, including
peptides, steroids, and inflammatory
lipid mediators (Robbiani et al., 2000;
Borges-Walmsley et al., 2003; Reid
et al., 2003). Therefore, it is further
understood that these efflux pumps
have, in addition to conferring resis-
tance of tumor cells to various chemo-
therapeutic drugs, crucial physiological
roles (Piddock, 2006). Several studies
have been carried out to investigate the
expression, regulation, and specific
substrates of ABC efflux transport
proteins, such as P-glycoprotein (P-gp)
and multidrug resistance-associated
proteins (MRP, gene name: ATP bind-
ing cassette C transporters, ABCC)
(Flens et al., 1996; Ishikawa et al.,
2000). Earlier it has been shown that
cells of the skin express a specific
pattern of several efflux proteins (Slee-
man et al., 2000; Baron et al., 2001;
Colone et al., 2008). Gene expression
analysis of normal human epidermal
keratinocytes (NHEK) showed constitu-
tive expression of MRP1 (ABCC1) as
well as MRP 3–7 (ABCC3–7), but was
negative for MDR1 and MRP2 (ABCC2)
(Baron et al., 2001). With regard to the
regulatory mechanisms of these trans-
port proteins in skin cells, it was shown
that the expression of different MRP
family members can be significantly
enhanced by IL-6-type cytokines.
Furthermore, upregulation of MRP ex-
pression was found in lesional skin
samples collected from patients with
inflammatory skin disorders such as
psoriasis and lichen planus (Dreuw
et al., 2005).
In this study, we provide evidence
for the functional MRP-mediated efflux
activity of NHEKs using an in vitro
transport assay. Therefore, the efflux
transport of various radiolabeled com-
pounds, including eugenol (4-allyl-2-
methoxyphenol), isoeugenol, estradiol
17beta-D-glucuronid (E217bG), oestrone-
3-sulfate, cyclosporine, and dexpanthe-
nol, was inhibited by the specific
MRP inhibitors, such as indomethacin
(Figure 1) (Draper et al., 1997; Zhou
et al., 2008) or MK571 (Figure 2)
(Skazik et al., 2008; Zhou et al.,
2008), and the intracellular accumula-
tion of these substrates was determined
after 15, 30, and 60 minutes. Cells not
treated with the inhibitor served as a
control. Treatment with indomethacin
at a concentration of 1 mM decreased
the efflux transport of [3H]E217bG up
to 6.5-fold and of [3H]oestrone-3-
sulfate up to 3.6-fold in NHEKs in
comparison with control transport mea-
sured in the absence of the inhibitor
(Figure 1a and b). Treatment of NHEKs
with MK571 decreased the efflux
of [3H]E217bG in a concentration-
dependent manner at a concentration
of 25 mM up to 4.1-fold and at a con-
centration of 100mM up to 5.1-fold
(Figure 2a). MK571 strongly reduced
the efflux of [3H]oestrone-3-sulfate
as well in a concentration-dependent
manner, as the cells accumulated this
steroid hormone up to 3.2-fold using
25 mM of MK571 and up to 6.1-fold
using 100mM of the inhibitor (Figure 2b)
in comparison with control transport
that is measured in the absence of
the inhibitor. Indomethacin blocked
the efflux transport of [3H]eugenol up
to 1.6-fold compared with control
cells without indomethacin treatment
(Figure 1c). Treatment of cells with
indomethacin increased intracellular
concentration of [3H]isoeugenol only
slightly up to 1.1-fold (Figure 1d).
Treatment of NHEKs with MK571 at
concentrations of 100 mM and 25 mM
decreased efflux transport of [3H]euge-
nol and [3H]isoeugenol, respectively, to
1.6-fold after 60 minutes of incuba-
tion (Figure 2c and d). Time course
experiments show stronger effects of
both inhibitors on the accumulation
of E217bG, oestrone-3-sulfate, eugenol,
and isoeugenol (Figures 1a–d and 2a–d)
in the cell after 60 minutes compared
with 15 or 30 minutes. This adds to the
suggestion that these effects are due to
the inhibition of efflux transport and
not due to influx transport. Treatment
of cells with indomethacin or MK571
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had only a minor effect on the transport
of [3H]cyclosporine and no influence
on the transport of [3H]dexpanthenol,
because a marginal or a corresponding
absence of alteration of intracellular accu-
mulation could be detected compared
with control cells without inhibitor treat-
ment (Figures 1e, f, 2e and f).
The human MRP subfamily consists
of at least nine members. Detailed
in vitro transport measurements, using
membrane vesicles purified from
MRP1-transfected cells, have shown
that MRP1 is a lipophilic anion trans-
porter, capable of transporting sulfate or
glucuronate conjugates, such as oes-
trone 3-sulfate or E217bG (Kruh et al.,
2001; Qian et al., 2001). Membrane
vesicles prepared from MRP3-trans-
fected HEK293 cells also transport the
prototypical MRP1 substrate E217bG,
but at a lower affinity. Both MRP1 and
MRP3 are constitutively expressed in
epidermal keratinocytes (Baron et al.,
2001), and active efflux transport of
their ligands E217bG and oestrone
3-sulfate in NHEKs was shown in this
study (Figures 1a, b, 2a and b).
In previous studies, we were able to
show that the active uptake of E217bG
and oestrone-sulfate in NHEKs is
mediated by organic anion transporting
proteins (Schiffer et al., 2003). In
addition this study demonstrated the
MRP-mediated efflux activity of NHEK
for sulfated estrogen (Figure 1b and
Figure 2b) and E217bG (Figure 1a and
Figure 2a), and thereby revealed, to our
knowledge for the first time, the cap-
ability of human skin cells for the
vectorial transport of compounds com-
bining OATP-mediated influx and
MRP-mediated efflux transport. This
direct interaction of structurally differ-
ent influx and efflux transporters has
been recently discovered in liver cells
by Liu et al. (2006).
Fragrances are worldwide a major
cause of allergic contact dermatitis, a
delayed-type hypersensitivity reaction
mediated by T lymphocytes. Studies by
Sieben et al. (2001) shown that meta-
bolic activation of eugenol using cyto-
chrome P450 enzymes may be essential
for positive T-cell responses to this
fragrance. In our studies, we could
show an MRP-mediated active transport
of the small-molecular-weight contact
allergens, eugenol and isoeugenol, in
human skin cells (Figures 1c, d, and 2c
and d), a novel mechanism that
might have a significant role in the
pathogenesis of contact allergy.
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Figure 1. The inhibitory effect of indomethacin on MRP-mediated efflux of various substrates in NHEKs. Cells were pre-incubated with the inhibitor
indomethacin (1 mM) for 15, 30, and 60 minutes at 37 1C. Control cells were treated with DMSO. Subsequently, the cells were exposed to various tritium-labeled
substrates including (a) E217bG (31010 mMml1, 2 mCi ml1), (b) oestrone-3-sulfate (1.15108 mMml1, 2mCi ml1), (c) eugenol (2 107 mMml1,
2mCi ml1), (d) isoeugenol (0.2 mMml1, 2 mCi ml1), (e) cyclosporine (1.25 107 mMml1, 2 mCi ml1), and (f) dexpanthenol (1 107 mMml1, 2 mCi ml1) in
the presence or the absence of the inhibitor. After incubation for 15, 30, or 60 minutes at 37 1C, the radioactive medium was removed and cells were washed.
The cells were lysed by adding scintillation fluid. The cell-associated radioactivity was determined. The values are expressed as counts per minute (c.p.m.).
Median values of three independent experiments in triplicate were used for statistical data analysis.
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Cyclosporine is an immunosuppres-
sive agents used in the setting of solid
organ and hematopoietic stem cell
transplantation, as well as inflammatory
skin diseases. It has been shown earlier
that cyclosporine A is a broad-spectrum
MDR modulator, effectively impairing
drug transport in cells overexpressing P-
gp, MRP1, BCRP, and LRP at the
clinically achievable concentrations.
Cyclosporine modulates drug transport
mediated by P-gp through competitive
inhibition, a mechanism that is inde-
pendent of that by which immunosup-
pression occurs. In addition, studies by
Fo¨rster et al. (2008) using canine
Madin-Darby cell line cells heterolo-
gously expressing MRP2 showed that
cyclosporine is a strong inhibitor of
MRP2-mediated transport of glutathione
methylfluorescein. Recently, it has been
shown that verapamil-induced inhibi-
tion of P-gp and other efflux transpor-
ters led to a significant increase in
cellular concentration and cytotoxic
effects of cyclosporine in normal hu-
man renal epithelial cells (Anglicheau
et al., 2006). Our studies showed only a
minor effect of MRP inhibitors on the
efflux transport of cyclosporine in skin
cells (Figures 1e and 2e). If cyclospor-
ine itself is a weak MRP substrate or if
transport activity is disturbed by con-
formational changes caused by 3H
labeling of the compound needs to be
addressed in further studies.
Pantothenic acid and its derivatives
are beneficial in the maintenance of
healthy skin and for cellular wound-
healing processes. Grafe et al. (2003)
showed that human keratinocytes ex-
press the sodium-dependent multivita-
min transporter mediating the influx
transport and intracellular accumula-
tion of pantothenic acid. Active efflux
transport of [3H]dexpanthenol could
not be detected in our study (Figures
1f and 2f), but further experiments using
pantothenate as a substrate should be
performed.
In addition to previous studies show-
ing the mRNA and protein expression of
efflux transport-associated proteins in
human epidermal keratinocytes, we
now provide data that strongly support
the functional role of these transport
proteins in the active efflux of com-
pounds relevant for skin physiology,
cell migration and proliferation, inflam-
mation, and tumor suppression.
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Figure 2. The inhibitory effect of MK571 on MRP-mediated efflux of various substrates in NHEKs. Cells were pre-incubated with the inhibitor MK571
(100mM, 25mM)) for 15, 30, and 60 minutes at 37 1C. Control cells were treated with DMSO. Subsequently, the cells were exposed to various tritium-labeled
substrates including (a) E217bG (31010 mMml1, 2 mCi ml1), (b) oestrone-3-sulfate (1.15108 mMml1, 2mCi ml1), (c) eugenol (2 107 mMml1,
2mCi ml1), (d) isoeugenol (0.2 mMml1, 2 mCi ml1), (e) cyclosporine (1.25 107 mMml1, 2 mCi ml1), and (f) dexpanthenol (1 107 mMml1, 2 mCi ml1)
in the presence or the absence of the inhibitor. After incubation for 15, 30, or 60 minutes at 37 1C, the radioactive medium was removed and cells were
washed. The cells were lysed by adding scintillation fluid. The cell-associated radioactivity was determined. The values are expressed as counts per minute
(c.p.m.). Median values of three independent experiments in triplicate were used for statistical data analysis.
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TO THE EDITOR
Omenn syndrome (OS) is a rare form of
severe combined immunodeficiency
characterized by an early onset of
generalized erythrodermia caused by a
massive auto-reactive T-cell infiltrate of
the skin. Activated T cells infiltrate the
skin, gut, liver, and spleen, resembling
graft-versus-host disease (Rieux-Laucat
et al., 1998).
Lymphocyte expression of surface
adhesion molecules and chemokineAbbreviation: OS, Omenn syndrome
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